@krispi thanks for posting the article.
For AD treatment, the intention is that Xanamem be part of a drug cocktail, not administered on its own.
For cognitive decline in other indications, I don't know if it would be administered on its own.
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis, page-5
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.004(11.4%) |
Mkt cap ! $84.08M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.3¢ | 3.0¢ | $501.2K | 16.01M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1647475 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 321203 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| ACW (ASX) Chart |